BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $429,692 | -37.5% | 1,513 | -23.7% | 0.02% | -35.7% |
| Q2 2022 | $687,387 | -38.4% | 1,983 | -23.0% | 0.03% | -26.3% |
| Q1 2022 | $1,115,511 | -31.1% | 2,576 | -17.7% | 0.04% | -30.9% |
| Q4 2021 | $1,618,757 | +125.1% | 3,129 | +110.8% | 0.06% | +103.7% |
| Q3 2021 | $719,102 | +25.4% | 1,484 | +16.5% | 0.03% | +22.7% |
| Q2 2021 | $573,631 | +40.6% | 1,274 | +19.3% | 0.02% | +22.2% |
| Q1 2021 | $407,901 | +110.6% | 1,068 | +75.1% | 0.02% | +80.0% |
| Q4 2020 | $193,706 | +31.9% | 610 | +2.9% | 0.01% | +25.0% |
| Q3 2020 | $146,904 | -8.4% | 593 | -2.3% | 0.01% | -20.0% |
| Q2 2020 | $160,290 | +13.3% | 607 | -18.6% | 0.01% | -16.7% |
| Q1 2020 | $141,457 | -30.7% | 746 | -19.8% | 0.01% | -20.0% |
| Q4 2019 | $204,144 | -3.3% | 930 | -13.8% | 0.02% | -11.8% |
| Q3 2019 | $211,128 | +3.3% | 1,079 | +10.1% | 0.02% | 0.0% |
| Q2 2019 | $204,320 | +0.1% | 980 | -4.7% | 0.02% | -10.5% |
| Q1 2019 | $204,109 | +63.8% | 1,028 | +19.4% | 0.02% | +26.7% |
| Q4 2018 | $124,604 | -22.2% | 861 | +9.7% | 0.02% | -16.7% |
| Q3 2018 | $160,226 | +49.6% | 785 | +8.4% | 0.02% | +20.0% |
| Q2 2018 | $107,116 | +109.8% | 724 | +114.2% | 0.02% | +87.5% |
| Q1 2018 | $51,052 | +497.1% | 338 | +412.1% | 0.01% | +700.0% |
| Q4 2017 | $8,550 | – | 66 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |